Barclays PLC Axsome Therapeutics, Inc. Put Options Transaction History

Barclays PLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	SELL	$69.39 - $97.64 $1.7 Million - $2.39 Million	-24,500 Reduced 47.12%	27,500 $2.2 Million
Q4 2023 Feb 15, 2024	BUY	$57.42 - $83.61 $2.99 Million - $4.35 Million	52,000 New	52,000 $4.14 Million
Q4 2021 Feb 14, 2022	SELL	$30.7 - $43.36 $1.81 Million - $2.55 Million	-58,800 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$19.91 - $68.26 $175,208 - $600,688	8,800 Added 17.6%	58,800 $1.94 Million
Q2 2021 Aug 13, 2021	BUY	$50.63 - $73.5 $2.28 Million - $3.31 Million	45,000 Added 900.0%	50,000 $3.37 Million

Q1 2020 May 13, 2020	SELL	$41.2 - $101.31 $1.03 Million - $2.53 Million	-25,000 Reduced 83.33%	5,000 $294,000
Q4 2019 Feb 10, 2020	BUY	$16.71 - $106.24 $452,841 - $2.88 Million	27,100 Added 934.48%	30,000 $3.1 Million
Q2 2019 Aug 14, 2019	SELL	$13.46 - $25.75 $1.11 Million - $2.13 Million	-82,800 Reduced 96.62%	2,900 $75,000
Q1 2019 May 15, 2019	BUY	$2.63 - $16.34 $225,391 - $1.4 Million	85,700 New	85,700 $1.22 Million

290

37.1M

401K

464K

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.38B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.